## Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Date: 12/11/2014

To Deputy Manager Dept. of Corporate Services, Bombay Stock Exchange Limited P J Towers, Dalal Street, Fort, MUMBAI - 400001

> Outcome of Board Meeting held on 12th November, 2014. Sub:

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 12th November 2014 and transacted following business:

1. Approved the Un Audited Financial Results for Quarter and Half year ending on 30th September,

We are herewith attaching the results sheet and Limited Review Report from Auditors of the company for the quarter and Half Year ended 30<sup>th</sup> September, 2014 pursuant Clause 41 of Listing agreement.

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram

Whole Time Director

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com

CIN No. L65993TG1987PLC007163

		16.1	15			14	13	12	111	10	9	œ	7		6	01		4	· co		T)									2				-		Sil	
	a)Basic	Earning Per Share(EPS)(Before Extraording	Balance sheet of previous accounts year	Accelves Excluding Revaluation Reserves as per	Research Capital(Face Value of Rs.10/-each)	Paid In Share Commission (11-12)	Net Profit/Loss for the Pariod/11 12	Extraordinary Items (Net of Tax oxposed for	Net Profit/Loss from Ordinary Activities at	Tax Expense	Profit/Loss from Ordinary Activities before 1. 77 av	Exceptional items  Exceptional items	costs but before occasion	Profit/(loss) from Ordinary activities after factor	Finance costs	costs and exceptional items/2.	Profit/(loss) from Ordinary activities before finance	Other income	finance cost and exceptions items(1-2)		Profit/loss from Operations before other	g. Total	1. Administrative Expenditure	f. Other Expenditure	e. Depreciation	d. Employees Cost	c. Purchase of traded goods	b. Consumption of Raw materials	a. Increase/(decrease) in stock in trade	Expenses	Total Income from operations	b) Other Operating Income	a) Net Sales/Income from Operation	Income from Operations	ANTICULARS	S.No. PARTICITY AND	realistative state of the quarter and Half year ended
0.11		0.00		- Constitution	935.05	10.63	0.00	10.63	2.66	13.29	0.00	13.29		10.76	24.04	100000000000000000000000000000000000000	19.46	4.59	}		344.84	196.66		40.28	53.67	0.00	68.44	-14.20		349.43	0.00	349.43		Unaudited	30-Sep-14		OI SHIRSAN INTERNATION
-0.14		•		935.05	07.57	12 10	0.00	-13.10	0.00	-13.10	0.00	-13.10		10.15	-2.95		22.50	-25.45			392.09	225.00		41.56	54.60	0.00	70.92	0.00		366.64	0.00	366.64		Unaudited	30-Jun-14	OUARTER ENDED	the quarter and Hal
210	0000	000		935.05	16.65	0.00	0.00	16.65	210	18.75	0.00	18.75	4100	853	27.28		21.00	6.28			351 62	EK 05		39.18	52 56	0.00	203.03	0.00	00.100	357 90	000	357.90	Dattonmen	Linaudihad		The same of the	f year ended on 30th
	0.00		20.00	935.05	-2.46	0.00	-2.46	2.66	0.13	0.00	67.0	040	20.90	21.09	3	41.96	0000	-20.86		736.93	421.66		01.84	77.80T	0.00	139.36	14.20	14.30	716.07	0.00	/0.0/	71000	Unaudited	30-Sep-14	HALF YEA	on som september, 2014	Contombo 2014
	0.00		935.05	035.07	15.00	0.00	15.09	5.87	20.96	0.00	20.96		0.00	20.96		20.25	0.71	1		394.80	288.30		43.20	63.30	0.00	0.00	0.00		395.51	0.00			Unaudited	30-Sep-13	HALF YEAR ENDED		
			935.05	29.3/			29.37	38.33	67.70	0.00	67.70		39.29	106.99		88.29	18.70			1593.86	946.14		156.25	222.80		294.97	-26.31		1612,55	0.00	1612.55		Audited	31-Mar-14	YEAR ENDED		Rs. In Lacs

PART-I

men?




held of 2 Status Pendi 3 The co 4 The D Place: Hyderabad Date: 12/11/2014	Notes:	E 1:10	(a) :F	49 00			2	1	Þ		16.ii	
held on 12th November, 2014 and a limited review of the same has been carried out by the statutory auditors of the company 2 Status of complaints from the investors during the quarter ended 30th September, 2014  The company Operates in Only one Segment  The Deprication is calculated as per the Companies Act, 1956  For VIVO BIO TECH LTD  M. Kalvan Ram  M. Kalvan Ra	(as a % of the total sharecapital of the company)	Promoter Group) Percentage of Shares	:Percentage of Shares	b) Non-Encumbered  Number of Shares	Promoter Group)  Percentage of Shares  as a % of the rest of	a) Pledged/Encumbered :Number of Shares :Percentage of Shares (as a % of the total shareholding of process)	Promoters and Promoter Group Shareholding		Particulars of Shareholding	b) Diluted	b)Diluted Earning Per Share(EPS)(After Extraordinary items) a) Basic	
e and approved by the same has been care e same has been care ere ended 30th Septs resolved - 1 Nos., 1956  For V	68.70%	100%	6424083	0	0.00	0	31.30%	2026427	elect Information fo	0.11	0.11	
wed by the Board of Directors in their meeting been carried out by the statutory auditors of the α 30th September, 2014  1 Nos., Complaints lying unresolved - 0 No.  For VIVO BIO TECH LTD	68.70%	100%	6424083	0	0.00	0	31.30%		or the Qtr and half y	-0.14	-0.14	
ory auditors of the corresolved - 0 No.	68.70%	100%	6424083	0	0.00	0	2926437 31.30%		PART -II- Select Information for the Qtr and half year ended on 30/09/2014	0.18	0.18	
mpany	68.70%	100%	6424083	0	0.00	0	2926437 31.30%		-0.03	-0.03	-0.03	
	68.70%	100%	6424083	0	0.00	0	2926437 31.30%		0.16	0.16	0.16	
	68.70%	100%	6424083	0.00	0.00	0.00	2926437 31.30%		0.31	0.31	0.31	

## Vivo Bio Tech Ltd.

Your Drug Discovery Partner

	and	Liabilities as on 30/09/2014	
	Particulars	As AT 30/09/2014	In Rupees
Α	EQUITY AND LIABILITIES	Unaudited	As at 31/03/2014
1	Shareholders' funds	Chaddited	Audited
	a) Share Capital		
	b) Reserves and Surplus	02.500	
		93,505,200	93,505,2
	Sub-total -Shareholders' Fun	(14,433,887)	(8,216,4
2	Non-Current Liabilities	79,071,313	85,288,7
	all one Term		
1	a)Long Term borrowings		
	b) Deffered tax liabilities	34,973,449	35,459,7
	c)Other Long term liabilities	14,256,739	14,256,73
- 1	d) Long term provisions		1,720,73
3	Sub-total -Non-Current Liabilities	s	1,297,40
	- Liabilities .	49,230,188	51,013,92
- 1	a) Short-term Borrowings		1,010,02
- 1	b) Trade Payables	30,421,502	30,769,84
- 1	c)Other Curren Liabilities	89,678,591	
- 1	d) Short Term provisions	161,687,543	85,471,626 102,756,377
- 1	Sub-total -Current Liabilities	44,040,683	45,147,781
		325,828,319	264,145,626
В	TOTAL-EQUITY AND LIABILITIES		204, 145,626
" JAS	SSETS LIABILITIES	454,129,820	400 440 440
1 No			400,448,309
No	n-Current Assets		
	a)Fixed Assets		
	i)Tangible Assets		
- 1	ii) Intangible Assets	157,026,889	147
	b) Non-Current investments	53,207,818	147,930,488
	c)Deffered tax assets(net)	1,371,875	56,720,467
1 3	d) Long term loans and advances		1,371,875
е	Other non-current assets		
v 100	Sub-total Non C	261,106	
Curr		211,867,688	321,955
a) In	ventories	,,	206,344,784
b) Tra	ade Receivables	1,650,509	100000000000000000000000000000000000000
c)Cas	h and cash equivalents	57,020,749	3,070,509
a) sho	ort term loans and advances	96,826,914	43,046,510
e) Our	er current assets	79,663,075	112,359,463
Sub-to	etal Current Assets	7,100,884	31,166,567
	and the same of th	242,262,132	4,460,476
TOTAL	ASSETS	7-5-1,252	194,103,525
		454,129,820	400 440
	Fo	M. Kalyan Ran	400,448,309

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com CIN No. L65993TG1987PLC007163



Tel. : (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

: (91-40) 2339 2474 Fax : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

To The Board of Directors M/s. Vivo Bio Tech Limited Hyderabad

## Limited Review Report for the guarter ended 30<sup>th</sup> September 2014

We have reviewed the accompanying statement of unaudited financial results of M/s...Vivo Bio Tech Limited for the quarter ended 30th September 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400. Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The company is in the process of reviewing the useful life of tangible fixed assets and identification of their major components, to enable it to provide depreciation on such assets in accordance with Schedule II of the Companies Act, 2013. Pending this, the depreciation on such assets has been provided for in accordance with Schedule XIV of the Companies Act, 1956. The effect to this is not quantified.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

hartered Accountants

Partner

Place: Hyderabad

Date: 12th November 2014

MUKUND VIJAYARAO JOSHI Chartered Accountant Membership No:024784